Form 4: Axsome Therapeutics Director Acquires Stock Options in Lieu of Cash Compensation

Director Roger Jeffs acquired 1,408 stock options in Axsome Therapeutics in lieu of cash compensation on February 21, 2025.

Summary

• On February 21, 2025, Roger Jeffs, a director of Axsome Therapeutics, Inc., acquired 1,408 stock options.
• These options were received in lieu of cash compensation earned in 2024.
• The exercise price of the options is $137.75.
• The options are immediately exercisable and expire on February 20, 2035.
• Following the transaction, Jeffs directly owns 1,408 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction of a director receiving stock options as part of their compensation. It doesn't inherently indicate positive or negative performance for the company.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard practice for compensating directors and aligning their interests with those of the shareholders. Stock options incentivize directors to work towards increasing the company's stock value.

Comparison to Industry Standards

• Granting stock options to directors is a common practice across the pharmaceutical industry.
• Companies like Biogen, Amgen, and Gilead Sciences also use stock options as part of their compensation packages for directors.
• The specific number of options and exercise price would be determined by the company's compensation policy and the director's contribution.

Related Party Transactions

• The grant of stock options to Roger Jeffs, a director, is a related party transaction.

Stakeholder Impact

• Shareholders may view this as a positive sign, aligning the director's interests with the company's performance.
• Employees may see this as a standard compensation practice for directors.

Key Dates